What is the price-to-earnings ratio of Agenus?
The price-earnings ratio of Agenus is currently -1.59.
Agenus P/E 2024
Agenus P/E
-1.59
Ticker
AGEN
ISIN
US00847G7051
WKN
A1JLKZ
As of Jul 17, 2024, Agenus's P/E ratio was -1.59, a -31.17% change from the -2.31 P/E ratio recorded in the previous year.
The Agenus P/E history
Agenus Aktienanalyse
What does Agenus do?
Agenus Inc is a leading biotech company specialized in the development of immunotherapies for the treatment of cancer and other serious diseases. The company was founded in 1994 and is headquartered in Lexington, Massachusetts. Agenus started as a small start-up company focusing on the research of antibodies against chronic viral diseases. In 2000, the company developed the first approved therapeutic vaccine against cervical cancer in collaboration with GlaxoSmithKline. Since then, Agenus has expanded its business to the discovery, development, and commercialization of novel antibody and immunotherapies. The company has brought many groundbreaking medications to the market, including a cancer immunotherapy called Prophage, which is approved for the treatment of glioblastoma, an aggressive brain tumor. Agenus' business model focuses on the development of immunotherapies that utilize the body's immune system to fight against cancer or other diseases. The company's research and development programs are divided into three areas: antibody development, immunotherapy, and preclinical developments. Agenus has a comprehensive library of antibodies and utilizes them to develop new and innovative antibodies and antibody conjugates that can be used to treat cancer and autoimmune diseases. The company has also developed a range of immunotherapies aimed at supporting the body's immune system in fighting against cancer and other diseases, including therapies targeting checkpoint inhibitors that enhance the body's immune response to cancer cells. In addition, Agenus has a broad portfolio of preclinical programs aimed at developing new drugs and therapies for the treatment of cancer and other diseases. Agenus has introduced a range of products to the market that can be used for the treatment of cancer and other diseases, including Prophage, a personalized cancer vaccine tailored to each patient for the treatment of glioblastoma. Other products include Zalifrelimab, a checkpoint inhibitor that aims to enhance the body's immune response to cancer, INCAGN2385, another checkpoint inhibitor that enhances T-cell activity in the body, and INCAGN1949, an antibody therapy targeting the GITR protein that can help enhance the immune response against cancer cells. In summary, Agenus is a leading biotech company specialized in the development of immunotherapies for the treatment of cancer and other serious diseases. The company has a long history in antibody research and development and has expanded its efforts to develop immunotherapies. Agenus has a comprehensive library of antibodies and has introduced a range of products to the market for the treatment of cancer and other diseases. With a broad portfolio of products and preclinical programs, Agenus remains a key player in the field of immunotherapies and is expected to drive further groundbreaking developments in the future. Agenus ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/E Details
Deciphering Agenus's P/E Ratio
The Price to Earnings (P/E) Ratio of Agenus is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.
Year-to-Year Comparison
Assessing Agenus's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.
Impact on Investments
The P/E ratio of Agenus is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.
Interpreting P/E Ratio Fluctuations
Fluctuations in Agenus’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.
Frequently Asked Questions about Agenus stock
How has the price-earnings ratio of Agenus changed compared to last year?
The price-to-earnings ratio of Agenus has increased by -31.17% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Agenus high compared to other companies?
Yes, the price-to-earnings ratio of Agenus is high compared to other companies.
How does an increase in the price-earnings ratio of Agenus affect the company?
An increase in the price-earnings ratio of Agenus would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Agenus affect the company?
A decrease in the price-earnings ratio of Agenus would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Agenus?
Some factors that influence the price-earnings ratio of Agenus are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Agenus pay?
Over the past 12 months, Agenus paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Agenus is expected to pay a dividend of 0 USD.
What is the dividend yield of Agenus?
The current dividend yield of Agenus is .
When does Agenus pay dividends?
Agenus pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Agenus?
Agenus paid dividends every year for the past 0 years.
What is the dividend of Agenus?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Agenus located?
Agenus is assigned to the 'Health' sector.
Wann musste ich die Aktien von Agenus kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Agenus from 7/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/17/2024.
When did Agenus pay the last dividend?
The last dividend was paid out on 7/17/2024.
What was the dividend of Agenus in the year 2023?
In the year 2023, Agenus distributed 0 USD as dividends.
In which currency does Agenus pay out the dividend?
The dividends of Agenus are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Agenus
Our stock analysis for Agenus Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Agenus Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
